Please Note
We brought you to this page based on your search query. If this isn't what you are looking for, you can continue to Search Results for ""
The maximum number of items you can export is 3,000. Please reduce your list by using the filtering tool to the left.

You Browsed By:

You Searched For:

or Browse by...




Find An Analyst


North America


  • 25 Apr 2018
    • Outlook for E&P sector remains positive on production and EBITDA growth amid capital efficiency focus
      EBITDA will continue to grow strongly over the next 12 to 18 months, even as commodity prices stay within a moderate range, although higher costs could cut into cash flow. Full Report
  • 19 Apr 2018
    • Stable outlook for global pharmaceuticals, but M&A event risk is rising
      Our stable outlook and modest EBITDA growth reflect solid underlying fundamentals, including rising utilization of prescription drugs, expansion in emerging markets and positive pricing trends in the US in many therapeutic areas; nonetheless, M&A event risk is rising, reflecting longer-term pressures that will have a growing impact beyond the 12-18 month outlook period.   Full Report
  • 17 Apr 2018
    • Healthcare Quarterly looks at credit impact of planned mergers in US healthcare
      Over the past few months, healthcare companies have announced a slew of transactions that continue to blur the lines between traditional healthcare segments and players, with differing credit consequences. Full Report​​
Please refine your search by Market Segment to get corresponding Rating Activity and Watchlist
Complete Your Profile
Please complete your profile before submitting your comments.
We're Sorry
  • Disclaimer:

  • Moody’s Credit Assessment™ is provided by Moody’s Credit Assessment, Inc. Moody’s Credit Assessment™ is not a Moody’s Investors Service credit rating and is solely based on publicly available information.